Press release
Limb Girdle Muscular Dystrophy Therapeutics Market Size in the 7MM is expected to increase substantially by 2034, estimates DelveInsight
Discover Key Insights into the Limb Girdle Muscular Dystrophy Market with DelveInsight's In-Depth Report @ Limb Girdle Muscular Dystrophy Treatment Market Size [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Limb Girdle Muscular Dystrophy Market Report
* On October 27, 2025 (Monday), BridgeBio Pharma Inc . announced positive topline results from its Phase 3 FORTIFY study evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMD2I/R9), as reported by Nasdaq (via RTTNews). The trial successfully met all primary and secondary endpoints, showing a 1.8-fold increase in glycosylated DG at three months, which was sustained through 12 months. It also demonstrated an 82% reduction in serum creatine kinase levels compared to placebo. Patients exhibited clinically meaningful improvements in functional outcomes, including a 0.14 m/s gain from baseline and 0.27 m/s versus placebo in the 100-meter timed test. Moreover, forced vital capacity improved by approximately 3% from baseline and 5% versus placebo.
* On 06 October 2025, Atamyo Therapeutics announced a ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5). Patients will be treated sequentially in 2 dose-cohorts.
* On 06 October 2025, AskBio Inc. conducted a study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
* According to DelveInsight's estimates, the total prevalent cases of Limb Girdle Muscular Dystrophy affects males and females in equal numbers. The prevalence of Limb Girdle Muscular Dystrophy is unknown, but estimates range from one in 14,500 to one in 123,000 and is expected to rise during the study period [2020-2034]. Estimates show the highest prevalent cases of Limb Girdle Muscular Dystrophy is in the United States followed by Europe.
* According to the findings, the age of onset can vary greatly even among individuals of the same family. The relative frequencies of the different types of LGMD vary from case to case, but worldwide LGMD2G, 2H and 2J are extremely rare.
* As per DelveInsight's estimates, LGMD prevalence across Europe ranges from 0.8 to 6 per 100,000.
* According to the findings, in the UK, dominantly inherited LGMD is less common and reported to be only 5-10% of all LGMD. It is also suggested that within the population of Northern England, LGMD accounts for 6.2% of all neuromuscular patients.
* The leading Limb Girdle Muscular Dystrophy Companies such as ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma , and others.
* Promising Limb Girdle Muscular Dystrophy Therapies such as SRP-9005, Corticosteroid, SRP-9003, Glucocorticoid, Deflazacort, ATYR1940, Prednisone , and others.
Stay ahead in the Limb Girdle Muscular Dystrophy Therapeutics Market with DelveInsight's Strategic Report @ Limb Girdle Muscular Dystrophy Market Outlook [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Limb Girdle Muscular Dystrophy Epidemiology Segmentation
* Total Limb Girdle Muscular Dystrophy Prevalent Cases
* Limb Girdle Muscular Dystrophy Type-specific Prevalent Cases
* Limb Girdle Muscular Dystrophy Subtype-specific Prevalent Cases
* Limb Girdle Muscular Dystrophy Diagnosed and Treatable Cases
Download the report to understand which factors are driving Limb Girdle Muscular Dystrophy Epidemiology trends @ Limb Girdle Muscular Dystrophy Prevalence [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Limb Girdle Muscular Dystrophy Emerging Drugs
* BBP-418: Bridge Bio
BridgeBio is pioneering an oral therapy, BBP-418, for limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This treatment targets the dysfunctional alpha-dystroglycan protein, addressing the underlying cause of muscle weakness. The Phase II data shows potential for functional improvements and reduced muscle breakdown. BBP-418 has received Fast Track and Orphan Drug designations from FDA and is currently in Phase III clinical trials.
* SRP-9003: Sarepta Therapeutics
Sarepta Therapeutics is actively involved in the development of gene therapies for Limb-Girdle Muscular Dystrophy (LGMD). The company has multiple LGMD gene therapy programs in progress, including LGMD2E/R4, LGMD2D, LGMD2C, LGMD2B, LGMD2L, and LGMD2A, collectively addressing over 70% of known LGMD cases.
* AB-1003 (LION-101): Asklepios Biopharmaceuticals/ Ask Bio
Asklepios Biopharmaceuticals' LION-101 is a cutting-edge therapy designed to combat LGMD by delivering a functional version of the FKRP gene to the body's cells. This innovative approach utilizes a recombinant adeno-associated virus, a viral vector known for its safety and ease of manipulation in laboratory settings. AB-1003 has secured Investigational New Drug (IND) clearance and Fast Track designation from the US FDA. It is currently advancing through Phase I/II clinical trials.
Limb Girdle Muscular Dystrophy Market Outlook
Major Limb Girdle Muscular Dystrophy Companies such as Bridge Bio, Sarepta Therapeutics, and Asklepios Biopharmaceuticals are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Limb Girdle Muscular Dystrophy (LGMD). The Limb Girdle Muscular Dystrophy Market Size in the seven major markets is expected to increase substantially from 2024.
Get In-Depth Knowledge on Limb Girdle Muscular Dystrophy Market Trends and Forecasts with DelveInsight @ Limb Girdle Muscular Dystrophy Therapeutics Market Size [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Limb Girdle Muscular Dystrophy Companies
ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma , and others.
Scope of the Limb Girdle Muscular Dystrophy Market Report
* Coverage- 7MM
* Forecast Period- 2024-2034
* Limb Girdle Muscular Dystrophy Companies- ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma , and others.
* Limb Girdle Muscular Dystrophy Therapies- SRP-9005, Corticosteroid, SRP-9003, Glucocorticoid, Deflazacort, ATYR1940, Prednisone , and others.
Unlock Strategic Insights with DelveInsight's Comprehensive Limb Girdle Muscular Dystrophy Market Report @ Limb Girdle Muscular Dystrophy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1 Key Insights
2 Limb Girdle Muscular Dystrophy Market Report Introduction
3 Limb Girdle Muscular Dystrophy Executive Summary
4 Limb Girdle Muscular Dystrophy Key Events
5 Limb Girdle Muscular Dystrophy Epidemiology and Market Forecast Methodology
6 Limb Girdle Muscular Dystrophy (LGMD) Market Overview at a Glance
7 Limb Girdle Muscular Dystrophy Disease Background and Overview
8 Limb Girdle Muscular Dystrophy Diagnostic Algorithm
9 Limb Girdle Muscular Dystrophy Epidemiology and Patient Cases: 7MM
10. Limb Girdle Muscular Dystrophy Treatment
11. Limb Girdle Muscular Dystrophy Patient Journey
12. Limb Girdle Muscular Dystrophy Unmet Needs
13. Limb Girdle Muscular Dystrophy Emerging Drugs
14 Limb Girdle Muscular Dystrophy:7 Major Market Analysis
15 Limb Girdle Muscular Dystrophy KOL Views
16 Limb Girdle Muscular Dystrophy SWOT Analysis
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=limb-girdle-muscular-dystrophy-therapeutics-market-size-in-the-7mm-is-expected-to-increase-substantially-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Limb Girdle Muscular Dystrophy Therapeutics Market Size in the 7MM is expected to increase substantially by 2034, estimates DelveInsight here
News-ID: 4243563 • Views: …
More Releases from ABNewswire
Non-Cystic Fibrosis Bronchiectasis Competitive Landscape 2025: Clinical Trial An …
Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others.
According to DelveInsight's analysis, the global Non-Cystic Fibrosis Bronchiectasis pipeline features over 16 leading companies actively advancing more than 17 therapeutic candidates, with ongoing evaluations of their clinical trials, mechanisms of action, routes of administration, and developmental…
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market …
Potential Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies are TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
DelveInsight's analysis reveals a rising burden of Interstitial Lung Disease (ILD) across major markets, with over 1 million diagnosed prevalent cases reported in the 7MM in 2024 and numbers projected to grow by 2034. In the US, more than 80,000 cases of pulmonary hypertension associated with ILD (PH-ILD) were recorded…
Triple-Negative Breast Cancer Market Analysis 2034 - Competitive Landscape, Clin …
Leading triple-negative breast cancer companies such as G1 Therapeutics, Daiichi Sankyo, AstraZeneca, Zenith Epigenetics, Pfizer, OncoPep, Tesaro, Inc., NBE-Therapeutics AG, A&G Pharmaceutical Inc., Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, and others.
The triple negative breast cancer (TNBC) market size is estimated to reach ~USD 7 billion by 2034, registering a CAGR of 4.70% from 2025 to 2034, according to a new report by DelveInsight, a pharmaceutical market research firm. Rising incidence…
Triple Negative Breast Cancer Pipeline Outlook Report 2025: Tracking the Most Pr …
DelveInsight's "Triple Negative Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline…
More Releases for Limb
Critical Limb Ischemia Pipeline: Advancing Regenerative Therapies and Novel Inte …
The treatment landscape for Critical Limb Ischemia (CLI), the most severe form of peripheral arterial disease, is evolving rapidly as the limitations of conventional revascularization and amputation drive demand for novel therapeutic approaches. Breakthroughs in angiogenesis, stem cell therapies, gene therapy, and immunomodulation are reshaping the future of CLI management, offering hope for tissue regeneration and improved limb salvage outcomes.
DelveInsight's "Critical Limb Ischemia - Pipeline Insight, 2025" provides an in-depth…
Limb Prosthetics Market Size And Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- Limb Prosthetics Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027.
Limb Prosthetics Market Growth Driver
The limb prosthetics market is experiencing significant growth, driven by several key factors, including the rising prevalence of limb loss due to diabetes, vascular diseases, and traumatic injuries. As…
Pediatric Lower Limb Prosthetics Market
The "Pediatric Lower Limb Prosthetics Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Pediatric Lower Limb Prosthetics Market, 2024-2031
Verified Market Research's most recent report, "Pediatric Lower Limb Prosthetics Market: Global Industry Trends, Share, Size, Growth, Opportunity and…
Limb Prosthetics Market 2024 Strategic Assessment
In recent years, the global Limb Prosthetics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Limb Prosthetics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Lower Limb Rehabilitation Exoskeleton Robot | WALKBOT
The exoskeleton robotic rehabilitation devices made by WALKBOT provide robot-assisted gait training rehabilitation systems for musculoskeletal disabilities.
Walkbot Advanced solutions
The Walkbot, lower limb rehabilitation robot provides exciting customized 3-dimensional augmented reality exercise games so that their clients actually do not perceive the gait training as a form of therapy. Rather, they enjoy walking in interactive and ecologically natural or virtual environments as used by the software.
Game-Like Rehabilitation Training: Go World immerses…
Critical Limb Ischemia - Drug Pipeline Landscape, 2022
Critical limb ischemia is a serious form of peripheral arterial disease, or PAD where severe blockage in the arteries of the lower extremities (hands, feet and legs) occurs, which markedly reduces blood-flow. It results in severe pain and even skin ulcers or sores.
Peripheral artery disease causes chronic limb-threatening ischemia. Other causes of limb ischemia include embolisms, trauma and compartment syndrome.
The most common symptom of critical limb ischemia is ischemic…
